Based on our GSEA analysis which indicated that the activation of MYC targets genes is crucial for the poor survival outcome of patients in the high-risk group, we choose AZD5153 which could inhibit the transcription of MYC and E2F by targeting BRD4 bromodomains (Rhyasen et al. 2016) as potential candidate and consistently, a recent study showed that BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells (Schmitt et al. 2023). This evidence concerns the gene BRD4 and diffuse large B-cell lymphoma.